This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis Of The Leading Generic Players In 2013

List of Figures

Figure 1: Generics Manufacturing Landscape Assessment – FY2012 Corporate Revenue Growth vs. Operating Margin 20Figure 2: Generics Manufacturing Landscape Assessment – FY2012 Generics Sales Growth vs. Operating Margin 21Figure 3: FY2011 and FY2012 Leading Generic Pharmaceutical Companies by Revenue 27Figure 4: FY2012 Leading Generic Pharmaceutical Companies by YTY Revenue Growth 31Figure 5: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by Operating Income ($m) 35Figure 6: FY2012 Leading Generic Pharmaceutical Companies by YTY Operating Income Growth 38Figure 7: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by Operating Margin 42Figure 8: Top 30 Generic Pharmaceutical Landscape Assessment – FY2012 SG&A Expense vs. Operating Expense as a Percentage of Revenue 44Figure 9: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by SG&A Spending ($m) 45Figure 10: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by SG&A Spending as a Percentage of Revenue 50Figure 11: FY2012 Leading Generic Pharmaceutical Companies by SG&A Spending as a Percentage of Revenue, YTY Change 53Figure 12: FY2011 and FY2012 Leading Generic Pharmaceutical Companies by Operating Expense as a Percentage of Revenue 57Figure 13: FY2011 and FY2012 Leading Generic Pharmaceutical Companies by Debt-to-Assets Ratio 65Figure 14: FY 2011 and FY2012, Leading Generic Pharmaceutical Companies by Cash Ratio 68Figure 15: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by ROI 71Figure 16: Sun Pharmaceuticals: SWOT Analysis 73Figure 17: Sandoz: SWOT Analysis 76Figure 18: Pharmstandard: SWOT Analysis 79Figure 19: Teva Pharmaceuticals: SWOT Analysis 82Figure 20: Teva Generics Sales in US vs. Rest-of-World (ROW)1, 2009–2012 85Figure 21: Actavis: SWOT Analysis 87Figure 22: Mylan: SWOT Analysis 90Figure 23: Ranbaxy: SWOT Analysis 93Figure 24: Dr. Reddy's: SWOT Analysis 94Figure 25: Covidien: SWOT Analysis 95Figure 26: Hospira: SWOT Analysis 96

Companies Mentioned

Sun Pharmaceuticals: The Benchmark LeaderSandoz PharmstandardTeva PharmaceuticalsActavis Mylan Ranbaxy Dr. Reddy's Covidien Hospira

To order this report: Generic_Drug Industry: PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013

__________________________Contact Clare: clare@reportlinker.com US:(339) 368 6001 Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,514.37 +65.12 0.40%
S&P 500 1,879.55 +7.66 0.41%
NASDAQ 4,161.4580 +39.9120 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs